Art. -Nr.: HY-B0221

Amphotericin B

27 Cited Publications

Kundenbewertung

Based on 27 publication(s) in Google Scholar

Amphotericin B is a polyene antifungal agent against a wide variety of fungal pathogens. It binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 93.31%
CAS. Nr.: 1397-89-3
Formel: C₄₇H₇₃NO₁₇
Molecular Weight:924.08

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Amphotericin B Chemical Structure

CAS. Nr.: 1397-89-3

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (27)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Leishmania

Plasmodium

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	11.25 μM Compound: Amp	Cytotoxicity against human 786-O cells assessed as decrease in mitochondrial viability after 6 hrs by CMXRos staining based assay Cytotoxicity against human 786-O cells assessed as decrease in mitochondrial viability after 6 hrs by CMXRos staining based assay	[PMID: 29407968]
A549	IC₅₀	18.2 μg/mL Compound: AmB	Cytotoxicity against human A549 cells assessed as reduction in cell survival Cytotoxicity against human A549 cells assessed as reduction in cell survival	[PMID: 27769670]
A549	IC₅₀	11.25 μM Compound: Amp	Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay	[PMID: 29407968]
BEAS-2B	IC₅₀	17.7 μg/mL Compound: AmB	Cytotoxicity against human BEAS2B cells assessed as reduction in cell survival Cytotoxicity against human BEAS2B cells assessed as reduction in cell survival	[PMID: 27769670]
BJ	IC₅₀	>50 μM Compound: Amphotericin B	Cytotoxicity against human BJ cells after 24 hrs by redox-sensitive dye based fluorescent assay Cytotoxicity against human BJ cells after 24 hrs by redox-sensitive dye based fluorescent assay	[PMID: 33091607]
BMDM	IC₅₀	>10 μM Compound: AmB	Cytotoxicity against mouse BMDM cells assessed as cell viability measured after 72 hrs by MTT assay Cytotoxicity against mouse BMDM cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 31299585]
BT-549	IC₅₀	5.5 μg/mL Compound: amphotericin B	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay	[PMID: 19105653]
CCRF-CEM	IC₅₀	160 μM Compound: Amphotericin B	Cytotoxicity against human CEM cells after 96 hrs Cytotoxicity against human CEM cells after 96 hrs	[PMID: 16124785]
CFPAC-1	IC₅₀	>10 μM Compound: AmB	Cytotoxicity against human CFPAC-1 cells assessed as cell viability measured after 72 hrs by MTT assay Cytotoxicity against human CFPAC-1 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 31299585]
CHO	GI₅₀	10.3 μg/mL Compound: Amphotericin B	Cytotoxicity against CHO cells assessed as cell viability after 48 hrs by MTT colorimetric assay Cytotoxicity against CHO cells assessed as cell viability after 48 hrs by MTT colorimetric assay	[PMID: 22551062]
Erythrocyte	IC₅₀	3.9 μg/mL Compound: amphotericin B	Toxicity in RBC assessed as hemolysis Toxicity in RBC assessed as hemolysis	[PMID: 19105653]
Erythrocyte	EC₅₀	2 μM Compound: 1, AMB	Hemolytic activity against human erythrocytes after 18 hrs by spectrophotometry Hemolytic activity against human erythrocytes after 18 hrs by spectrophotometry	[PMID: 22959766]
HEK293	CC₅₀	4.2 μM Compound: Amphotericin B	Cytotoxicity against HEK293 cells after 43 hrs by Alamar blue dye-based fluorescence assay Cytotoxicity against HEK293 cells after 43 hrs by Alamar blue dye-based fluorescence assay	[PMID: 29243920]
HEK293	IC₅₀	78.62 μM Compound: Amphotericin B	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 29626797]
HEK293	IC₅₀	15 μg/mL Compound: AmB	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31498627]
HEK-293T	CC₅₀	36.49 μM Compound: Amphotericin B	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 29328999]
HEK-293T	CC₅₀	27.46 μM Compound: Amphotericin B	Cytotoxicity against HEK293T cells after 72 hrs by CCK8 assay Cytotoxicity against HEK293T cells after 72 hrs by CCK8 assay	[PMID: 29541366]
HeLa	IC₅₀	0.5 μM Compound: Amphotericin B	Antifungal activity against Candida albicans SC5314 infected in HeLa cells after 5 days by fluorescein diacetate assay Antifungal activity against Candida albicans SC5314 infected in HeLa cells after 5 days by fluorescein diacetate assay	[PMID: 21711055]
HeLa	IC₅₀	10 μM Compound: amphotericin B	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26204500]
HEp-2	CC₅₀	87 U/mg Compound: AmB	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 40 to 60 mins by resazurin dye based assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 40 to 60 mins by resazurin dye based assay	[PMID: 35178173]
HEp-2	CC₅₀	87 μg/mL Compound: AmB	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 40 to 60 mins by resazurin dye based assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 40 to 60 mins by resazurin dye based assay	[PMID: 35178173]
HepG2	IC₅₀	10 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19482476]
HepG2	CC₅₀	8.8 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22608675]
HepG2	CC₅₀	8.8 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24080103]
HepG2	IC₅₀	2.5 μM Compound: AMB	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 24953953]
HepG2	CC₅₀	40 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 48 hrs by resazurin based assay Cytotoxicity against human HepG2 cells after 48 hrs by resazurin based assay	[PMID: 25137549]
HepG2	CC₅₀	8.8 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 25559208]
HepG2	CC₅₀	8.8 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25846065]
HepG2	IC₅₀	3.1 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 43 hrs by Alamar blue dye-based fluorescence assay Cytotoxicity against human HepG2 cells after 43 hrs by Alamar blue dye-based fluorescence assay	[PMID: 29243920]
HepG2	CC₅₀	28.62 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay	[PMID: 29328999]
HepG2	CC₅₀	37.81 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay	[PMID: 29541366]
HepG2	CC₅₀	5.5 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29885575]
HepG2	CC₅₀	8.8 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
HepG2	CC₅₀	8.8 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30655943]
HepG2	CC₅₀	5.5 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32292551]
HepG2	CC₅₀	8.8 μM Compound: Amphotericin B	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
HepG2	CC₅₀	8.8 μM Compound: Arnphotericin B	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32795774]
HepG2	CC₅₀	4 μg/L Compound: AMB	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay	[PMID: 33335669]
HMEC-1	IC₅₀	25.7 μM Compound: Amph B	Cytotoxicity against HMEC1 cells after 72 hrs by MTT assay Cytotoxicity against HMEC1 cells after 72 hrs by MTT assay	[PMID: 25497962]
HMEC-1	IC₅₀	>10 μM Compound: AmB	Cytotoxicity against human HMEC1 cells assessed as cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HMEC1 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 31299585]
HT-29	IC₅₀	10 μM Compound: amphotericin B	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 26204500]
HUVEC	CC₅₀	4.92 μM Compound: AMB	Cytotoxicity against human HUVEC cells assessed as reduction in cell viability by CCK-8 assay Cytotoxicity against human HUVEC cells assessed as reduction in cell viability by CCK-8 assay	[PMID: 35788035]
HUVEC	IC₅₀	16 μg/mL Compound: AmB	Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 35922963]
HUVEC	CC₅₀	4.12 μg/mL Compound: AMB	Cytotoxicity against HUVEC cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against HUVEC cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37788549]
J774	IC₅₀	0.046 μM Compound: amphotericin B	Antileishmanial activity against Leishmania donovani in mouse J774 cells Antileishmanial activity against Leishmania donovani in mouse J774 cells	[PMID: 18006310]
J774	CC₅₀	9 μM Compound: Amphotericin B	Cytotoxicity against mouse J774 cells after 24 hrs by WST-1 assay Cytotoxicity against mouse J774 cells after 24 hrs by WST-1 assay	[PMID: 36508970]
J774.1	IC₅₀	>70 μM Compound: Amphotericin B	Antiproliferative activity against mouse J774.1 cells after 48 hrs by alamar blue assay Antiproliferative activity against mouse J774.1 cells after 48 hrs by alamar blue assay	[PMID: 19117415]
J774.1	IC₅₀	0.52 μM Compound: Amph	Cytotoxicity against mouse J774.1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse J774.1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23202852]
J774.1	CC₅₀	3.1 μM Compound: Amphotericin B	Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay	[PMID: 24080103]
J774.1	IC₅₀	2.5 μM Compound: Amphotericin B	Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay	[PMID: 25846065]
J774.A1	IC₅₀	0.00646 μg/mL Compound: amphotericin-B	Antiamastigote activity against Leishmania donovani MHOM IN/Dd8 in mouse J-774A.1 cells by luciferase reporter gene assay after 72 hrs Antiamastigote activity against Leishmania donovani MHOM IN/Dd8 in mouse J-774A.1 cells by luciferase reporter gene assay after 72 hrs	[PMID: 17306422]
J774.A1	CC₅₀	7.24 μg/mL Compound: Amphotericin B	Cytotoxicity against mouse J774A1 cells by MTT assay Cytotoxicity against mouse J774A1 cells by MTT assay	[PMID: 19913413]
J774.A1	IC₅₀	3.14 μM Compound: Amphotericin B	Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay	[PMID: 21555166]
J774.A1	CC₅₀	3.1 μM Compound: Amphotericin B	Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay	[PMID: 22608675]
J774.A1	CC₅₀	3.7 μM Compound: Amphotericin B	Cytotoxicity against mouse J774A1 cells after 48 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 48 hrs by MTT assay	[PMID: 24398381]
J774.A1	EC₅₀	40 μM Compound: Amphotericin B	Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/L82 infected in mouse J774A1 cells by colorimetric assay Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/L82 infected in mouse J774A1 cells by colorimetric assay	[PMID: 24874647]
J774.A1	EC₅₀	89 μM Compound: Amphotericin B	Antileishmanial activity against intracellular amastigote stage of Leishmania amazonensis LV78 infected in mouse J774A1 cells by colorimetric assay Antileishmanial activity against intracellular amastigote stage of Leishmania amazonensis LV78 infected in mouse J774A1 cells by colorimetric assay	[PMID: 24874647]
J774.A1	CC₅₀	6.91 μM Compound: Amphotericin B	Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay	[PMID: 25282267]
J774.A1	IC₅₀	0.06 μM Compound: Amphotericin B	Antileishmanial activity against intracellular amastigote stage of Leishmania infantum MHOM/MA/67/ITMAP-263 expressing luciferase infected in mouse J774A1 cells assessed as inhibition of metabolic activity after 120 hrs by luminescence assay Antileishmanial activity against intracellular amastigote stage of Leishmania infantum MHOM/MA/67/ITMAP-263 expressing luciferase infected in mouse J774A1 cells assessed as inhibition of metabolic activity after 120 hrs by luminescence assay	[PMID: 25846065]
J774.A1	CC₅₀	16.8 μM Compound: Amp B	Cytotoxicity against mouse J774A1 cells assessed as decrease in cell viability after 48 hrs by MTT method Cytotoxicity against mouse J774A1 cells assessed as decrease in cell viability after 48 hrs by MTT method	[PMID: 27597410]
J774.A1	CC₅₀	60.7 μM Compound: Amph B	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability measured after 20 hrs by MTT assay Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability measured after 20 hrs by MTT assay	[PMID: 30784876]
J774.A1	CC₅₀	7 μM Compound: Amphotericin B	Cytotoxicity against mouse J774A1 cells after 48 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 48 hrs by MTT assay	10.1039/C3MD00388D
K562	IC₅₀	17 μM Compound: Amphotericin B	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19482476]
KB	IC₅₀	<25 μg/mL Compound: amphotericin B	Cytotoxicity against human KB cells after 48 hrs by neutral red assay Cytotoxicity against human KB cells after 48 hrs by neutral red assay	[PMID: 19105653]
L132	CC₅₀	5.4 μM Compound: Amp B	Cytotoxicity against human L132 cells assessed as inhibition of cell growth Cytotoxicity against human L132 cells assessed as inhibition of cell growth	[PMID: 36092146]
L929	CC₅₀	79.13 μM Compound: Amp B	Cytotoxicity against mouse L929 cells assessed as decrease in cell viability after 48 hrs by MTT method Cytotoxicity against mouse L929 cells assessed as decrease in cell viability after 48 hrs by MTT method	[PMID: 27597410]
LLC-MK2	CC₅₀	22.82 μM Compound: Amphotericin B	Cytotoxicity against monkey LLC-MK2 cells incubated for 72 hrs by MTT assay Cytotoxicity against monkey LLC-MK2 cells incubated for 72 hrs by MTT assay	[PMID: 37573209]
LLC-PK1	IC₅₀	2.4 μg/mL Compound: AMB	Cytotoxicity against LLC-PK1 cells by neutral red method Cytotoxicity against LLC-PK1 cells by neutral red method	[PMID: 17181171]
M109	IC₅₀	7.5 μg/mL Compound: amphotericin B	Cytotoxicity against mouse M109 cells Cytotoxicity against mouse M109 cells	[PMID: 9784152]
Macrophage	IC₅₀	>70 μM Compound: Amphotericin B	Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by alamar blue assay Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by alamar blue assay	[PMID: 19117415]
Macrophage	IC₅₀	5.3 μM Compound: Amphotericin B	Toxicity against BALB/c mouse macrophage by MTT assay Toxicity against BALB/c mouse macrophage by MTT assay	[PMID: 19962891]
Macrophage	IC₅₀	5.4 μM Compound: Amphotericin B	Cytotoxicity against BALB/c mouse macrophages after 48 hrs by trypan blue dye exclusion method Cytotoxicity against BALB/c mouse macrophages after 48 hrs by trypan blue dye exclusion method	[PMID: 20356752]
Macrophage	CC₅₀	>50 μM Compound: Amphotericin B	Cytotoxicity against Balb/c mouse peritoneal macrophage assessed as cell viability measured after 72 hrs by alamar blue assay Cytotoxicity against Balb/c mouse peritoneal macrophage assessed as cell viability measured after 72 hrs by alamar blue assay	[PMID: 32902988]
Macrophage	CC₅₀	1.06 μM Compound: AmB	Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 37793327]
MCF7	IC₅₀	60 μg/mL Compound: amphotericin B	Antiproliferative activity against human MCF7 cells assessed as cell viability by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability by MTT assay	[PMID: 17765545]
MEF	IC₅₀	6.6 μg/mL Compound: 1; AMB	Cytotoxicity against mouse MEF cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against mouse MEF cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26816333]
MRC5	CC₅₀	25 μM Compound: Amphotericin B	In Vitro cytotoxicity on MRC-5 cells In Vitro cytotoxicity on MRC-5 cells	[PMID: 10893302]
MRC5	CC₅₀	>32 μg/mL Compound: Amphotericin B	Cytotoxic concentration against human lung fibroblast MRC-5 cells Cytotoxic concentration against human lung fibroblast MRC-5 cells	[PMID: 15633999]
MRC5	EC₅₀	23 μM Compound: Am B	Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 27475107]
MRC5	CC₅₀	11.96 μM Compound: AmB	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31419778]
MRC5	IC₅₀	>50 μM Compound: Amphotericin B	Cytotoxicity against human MRC5 cells after 24 hrs by redox-sensitive dye based fluorescent assay Cytotoxicity against human MRC5 cells after 24 hrs by redox-sensitive dye based fluorescent assay	[PMID: 33091607]
NIH3T3	EC₅₀	2.2 μM Compound: Amphotericin B	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay	10.1039/C5MD00119F
PBMC	IC₅₀	>100 μM Compound: amphotericin B	Cytotoxicity against human PBMC by MTT assay after 3 to 4 days Cytotoxicity against human PBMC by MTT assay after 3 to 4 days	[PMID: 17049253]
PBMC	IC₅₀	96 μM Compound: amphotericin B	Cytotoxicity against human phytohemagglutininin-activated-PBMC by MTT assay after 3 to 4 days Cytotoxicity against human phytohemagglutininin-activated-PBMC by MTT assay after 3 to 4 days	[PMID: 17049253]
PBMC	IC₅₀	>5.41 μM Compound: Amphotericin B	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 24485783]
PBMC	CC₅₀	7.634 μg/mL Compound: Amphotericin B	Cytotoxicity against PBMC (unknown origin) Cytotoxicity against PBMC (unknown origin)	[PMID: 34311084]
Peritoneal macrophage	EC₅₀	9.18 μM Compound: AmpB	Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by MTT assay	[PMID: 28826085]
Peritoneal macrophage	CC₅₀	23.1 μM Compound: AmpB	Cytotoxicity against mouse peritoneal macrophages assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse peritoneal macrophages assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 30913526]
Peritoneal macrophage	CC₅₀	16.7 μM Compound: AmpB	Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38164929]
Peritoneal macrophage	IC₅₀	3.6 μM Compound: Amphotericin B	Cytotoxicity against mouse peritoneal macrophages assessed as cell viability after 48 hrs by hematocytometer Cytotoxicity against mouse peritoneal macrophages assessed as cell viability after 48 hrs by hematocytometer	[PMID: 20954722]
Peritoneal macrophage	CC₅₀	4.4 μM Compound: Anf B	Cytotoxicity against mouse peritoneal macrophages after 48 hrs by trypan blue exclusion method Cytotoxicity against mouse peritoneal macrophages after 48 hrs by trypan blue exclusion method	[PMID: 21724395]
Peritoneal macrophage	IC₅₀	7.4 μM Compound: amphotericin B	Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay	[PMID: 22989363]
Peritoneal macrophage	CC₅₀	25 μg/mL Compound: Amphotericin B	Cytotoxicity against mouse peritoneal macrophages after 72 hrs by MTT assay Cytotoxicity against mouse peritoneal macrophages after 72 hrs by MTT assay	[PMID: 23623672]
Peritoneal macrophage	CC₅₀	0.7 μM Compound: Amphotericin B	Cytotoxicity against mouse peritoneal macrophages after 24 hrs by MTT assay Cytotoxicity against mouse peritoneal macrophages after 24 hrs by MTT assay	[PMID: 24321832]
Peritoneal macrophage	EC₅₀	23.1 μM Compound: AmpB	Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 24 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 24 hrs by MTT assay	[PMID: 26055530]
Peritoneal macrophage	CC₅₀	27.1 μM Compound: Amphotericin B	Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 26112378]
Peritoneal macrophage	IC₅₀	53.37 μM Compound: Amphotericin B	Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]
Peritoneal macrophage	CC₅₀	0.18 μM Compound: Amphotericin B	Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay	[PMID: 26513640]
RAW	IC₅₀	0.04 μM Compound: amphotercin B	Antileishmanial activity against Leishmania donovani LV9 amastigotes infected in mouse RAW 264.7 cells after 72 hrs by MTT assay Antileishmanial activity against Leishmania donovani LV9 amastigotes infected in mouse RAW 264.7 cells after 72 hrs by MTT assay	[PMID: 12502308]
RAW	IC₅₀	0.04 μM Compound: amphotercin B	Antileishmanial activity against Leishmania infantum D.SCH amastigotes infected in mouse RAW 264.7 cells after 72 hrs by MTT assay Antileishmanial activity against Leishmania infantum D.SCH amastigotes infected in mouse RAW 264.7 cells after 72 hrs by MTT assay	[PMID: 12502308]
RAW264.7	IC₅₀	12 μM Compound: amphotericin B	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay	[PMID: 22989363]
RAW264.7	EC₅₀	20.44 μg/mL Compound: Amphotericin B	Antileishmanial activity against intracellular Leishmania infantum chagasi MHOM/BR/00/1669 amastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs Antileishmanial activity against intracellular Leishmania infantum chagasi MHOM/BR/00/1669 amastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs	[PMID: 25281268]
RAW264.7	EC₅₀	0.047 μM Compound: amphotericin B	Antiparasite activity against luciferase-expressing Leishmania major amastigotes isolated from infected in mouse RAW264.7 cells assessed as growth inhibition incubated for 96 hrs by luciferase reporter gene assay Antiparasite activity against luciferase-expressing Leishmania major amastigotes isolated from infected in mouse RAW264.7 cells assessed as growth inhibition incubated for 96 hrs by luciferase reporter gene assay	[PMID: 26087257]
RAW264.7	IC₅₀	0.031 μM Compound: Amphotericin B	Antileishmanial activity against Leishmania donovani MHOM/ET/67/HU3 amastigotes infected in mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by SYBR green 1 staining based fluorescence assay Antileishmanial activity against Leishmania donovani MHOM/ET/67/HU3 amastigotes infected in mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by SYBR green 1 staining based fluorescence assay	[PMID: 26774924]
RAW264.7	IC₅₀	10.02 μM Compound: AmpB	Cytotoxicity against mouse RAW264.7 cells after 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 48 hrs by MTT assay	[PMID: 28826085]
RAW264.7	CC₅₀	4.23 μM Compound: AmB	Cytotoxicity against mouse RAW264.7 cells after 48 hrs by resazurin dye-based assay Cytotoxicity against mouse RAW264.7 cells after 48 hrs by resazurin dye-based assay	[PMID: 30774860]
RAW264.7	CC₅₀	1 μM Compound: AMP	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30996772]
RAW264.7	ED₅₀	>5 μM Compound: Amphotericin B	Cytotoxicity against mouse RAW264.7 cells measured after 24 hrs by alamarBlue staining based fluorescence analysis Cytotoxicity against mouse RAW264.7 cells measured after 24 hrs by alamarBlue staining based fluorescence analysis	10.1039/C6MD00060F
RAW264.7	ED₅₀	0.195 μM Compound: Amphotericin B	Antileishmanial activity against Leishmania mexicana MNYC/BZ/62/M379 amastigotes infected in mouse RAW264.7 cells assessed as parasite viability measured after 24 hrs by alamarBlue staining based fluorescence analysis Antileishmanial activity against Leishmania mexicana MNYC/BZ/62/M379 amastigotes infected in mouse RAW264.7 cells assessed as parasite viability measured after 24 hrs by alamarBlue staining based fluorescence analysis	10.1039/C6MD00060F
SK-MEL	IC₅₀	5 μg/mL Compound: amphotericin B	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay	[PMID: 19105653]
SK-OV-3	IC₅₀	>25 μg/mL Compound: amphotericin B	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay	[PMID: 19105653]
Splenocyte	CC₅₀	>20 μM Compound: Amphotericin B	Cytotoxicity against mouse splenocytes by alamar blue assay Cytotoxicity against mouse splenocytes by alamar blue assay	[PMID: 27541264]
Splenocyte	CC₅₀	>20 μM Compound: AMB	Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 27639365]
Splenocyte	CC₅₀	>20 μM Compound: AMB	Cytotoxicity against BALB/c mouse splenocytes assessed as decrease in parasite viability after 72 hrs by Alamar blue assay Cytotoxicity against BALB/c mouse splenocytes assessed as decrease in parasite viability after 72 hrs by Alamar blue assay	[PMID: 29704722]
Splenocyte	CC₅₀	>20 μM Compound: AMB	Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability by alamar blue assay Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability by alamar blue assay	[PMID: 30408746]
THP-1	IC₅₀	154.5 μM Compound: amphotericin B	Cytotoxicity against human THP1 cells Cytotoxicity against human THP1 cells	[PMID: 17418916]
THP-1	CC₅₀	0.17 μM Compound: AmB	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 19321339]
THP-1	IC₅₀	0.01 μM Compound: AmB	Antiparasitic activity against Leishmania chagasi MHOM/BR/74/PP75 promastigotes infected in human THP1 cells after 72 hrs Antiparasitic activity against Leishmania chagasi MHOM/BR/74/PP75 promastigotes infected in human THP1 cells after 72 hrs	[PMID: 19321339]
THP-1	IC₅₀	14 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry	[PMID: 19748781]
THP-1	IC₅₀	0.1 μM Compound: Amphotericin B	Antileishmanial activity against Leishmania donovani MHOM/IN/80/DD8 amastigotes infected in human THP1 cells assessed as decrease of infected macrophages after 72 hrs by Giemsa staining Antileishmanial activity against Leishmania donovani MHOM/IN/80/DD8 amastigotes infected in human THP1 cells assessed as decrease of infected macrophages after 72 hrs by Giemsa staining	[PMID: 19914747]
THP-1	IC₅₀	14 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay	[PMID: 19914747]
THP-1	CC₅₀	8.79 μM Compound: AmB	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 20627590]
THP-1	IC₅₀	0.08 μM Compound: AmB	Antileishmanial activity against Leishmania chagasi MHOM/BR/74/PP75 amastigotes infected in human THP1 cells after 5 days by Giemsa staining Antileishmanial activity against Leishmania chagasi MHOM/BR/74/PP75 amastigotes infected in human THP1 cells after 5 days by Giemsa staining	[PMID: 20627590]
THP-1	IC₅₀	1.2 μM Compound: Amphotericin B	Antileishmanial activity against Leishmania infantum MOM/MA671TMAP263 axenic amastigotes infected in THP1 cells after 72 hrs by luciferase reporter gene assay Antileishmanial activity against Leishmania infantum MOM/MA671TMAP263 axenic amastigotes infected in THP1 cells after 72 hrs by luciferase reporter gene assay	[PMID: 24119553]
THP-1	IC₅₀	23.8 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 24119553]
THP-1	IC₅₀	0.2 μM Compound: Amph. B	Antimicrobial activity against promastigote stage of Leishmania donovani infected in human THP1 cells after 72 hrs by Alamar Blue assay Antimicrobial activity against promastigote stage of Leishmania donovani infected in human THP1 cells after 72 hrs by Alamar Blue assay	[PMID: 24980054]
THP-1	CC₅₀	7.57 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells infected with intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 Cytotoxicity against human THP1 cells infected with intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3	[PMID: 25036797]
THP-1	EC₅₀	0.22 μM Compound: Amphotericin B	Antileishmanial activity against extracellular promastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells incubated for 28 hrs followed by additional 20 hrs incubation by confocal microscopy Antileishmanial activity against extracellular promastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells incubated for 28 hrs followed by additional 20 hrs incubation by confocal microscopy	[PMID: 25036797]
THP-1	EC₅₀	0.25 μM Compound: Amphotericin B	Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells after 3 days by confocal microscopy Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells after 3 days by confocal microscopy	[PMID: 25036797]
THP-1	CC₅₀	29.7 μM Compound: AmB	Cytotoxicity against human THP1 cells Cytotoxicity against human THP1 cells	[PMID: 25173828]
THP-1	IC₅₀	0.01 μM Compound: AmB	Antiparasitic activity against amastigote stage of Leishmania infantum infected in THP1 cells assessed as parasite growth inhibition after 24 hrs by hemocytometery Antiparasitic activity against amastigote stage of Leishmania infantum infected in THP1 cells assessed as parasite growth inhibition after 24 hrs by hemocytometery	[PMID: 25173828]
THP-1	IC₅₀	0.03 μM Compound: AmB	Antiparasitic activity against promastigote stage of Leishmania infantum infected in THP1 cells assessed as parasite growth inhibition after 24 hrs by hemocytometery Antiparasitic activity against promastigote stage of Leishmania infantum infected in THP1 cells assessed as parasite growth inhibition after 24 hrs by hemocytometery	[PMID: 25173828]
THP-1	IC₅₀	>10 μg/mL Compound: Amphotericin B	Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
THP-1	IC₅₀	0.2 μg/mL Compound: Amphotericin B	Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
THP-1	EC₅₀	0.24 μM Compound: Amb	Anti-leishmanial activity against Leishmania major MHOM/JL/80/ Friedlin amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay Anti-leishmanial activity against Leishmania major MHOM/JL/80/ Friedlin amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay	[PMID: 25462252]
THP-1	EC₅₀	0.28 μM Compound: Amb	Anti-leishmanial activity against Leishmania donovani MHOM/IND/80/Dd8 amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay Anti-leishmanial activity against Leishmania donovani MHOM/IND/80/Dd8 amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay	[PMID: 25462252]
THP-1	EC₅₀	14.32 μM Compound: Amb	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 25462252]
THP-1	CC₅₀	8.4 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 25559208]
THP-1	IC₅₀	0.16 μM Compound: Amphotericin B	Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI intracellular amastigotes infected in human THP1 cells assessed as reduction in parasite-infected macrophages incubated for 120 hrs by Giemsa staining based microscopy Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI intracellular amastigotes infected in human THP1 cells assessed as reduction in parasite-infected macrophages incubated for 120 hrs by Giemsa staining based microscopy	[PMID: 25559208]
THP-1	IC₅₀	0.16 μM Compound: Amphotericin B	Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/IN/00/DEVI infected in human THP1 cells assessed as decrease infected macrophages after 120 hrs by microscopy Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/IN/00/DEVI infected in human THP1 cells assessed as decrease infected macrophages after 120 hrs by microscopy	[PMID: 25846065]
THP-1	IC₅₀	8.4 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 25846065]
THP-1	CC₅₀	10 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26906638]
THP-1	IC₅₀	0.07 μM Compound: Amphotericin B	Antileishmanial activity against intracellular amastigote stage of Leishmania amazonensis infected in human THP1 cells after 3 hrs by microplate based assay Antileishmanial activity against intracellular amastigote stage of Leishmania amazonensis infected in human THP1 cells after 3 hrs by microplate based assay	[PMID: 26906638]
THP-1	IC₅₀	0.1 μM Compound: Amphotericin B	Antileishmanial activity against Leishmania donovani MHOM/ET/67/HU3 intracellular amastigotes infected in human THP1 cells after 72 hrs by luciferase coupled luminescence assay Antileishmanial activity against Leishmania donovani MHOM/ET/67/HU3 intracellular amastigotes infected in human THP1 cells after 72 hrs by luciferase coupled luminescence assay	[PMID: 27155468]
THP-1	EC₅₀	0.09 μM Compound: Am B	Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells assessed as parasite growth measured after 72 hrs by luciferase reporter gene assay Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells assessed as parasite growth measured after 72 hrs by luciferase reporter gene assay	[PMID: 27475107]
THP-1	EC₅₀	38 μM Compound: Am B	Cytotoxicity against human THP1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 27475107]
THP-1	CC₅₀	27.86 μM Compound: AB	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28152426]
THP-1	CC₅₀	>50 μM Compound: Amph.B	Cytotoxicity against human THP1 cells measured after 72 hrs by resazurin assay Cytotoxicity against human THP1 cells measured after 72 hrs by resazurin assay	[PMID: 28434763]
THP-1	IC₅₀	>2 μg/mL Compound: AMB	Cytotoxicity against human THP1 cells Cytotoxicity against human THP1 cells	[PMID: 29023124]
THP-1	CC₅₀	16.9 μM Compound: Amp	Cytotoxicity against human THP1 cells assessed as decrease in viable cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as decrease in viable cells after 72 hrs by MTT assay	[PMID: 29407968]
THP-1	CC₅₀	200 μM Compound: Amph B	Cytotoxicity against human THP1 cells after 72 hrs by Alamar blue assay Cytotoxicity against human THP1 cells after 72 hrs by Alamar blue assay	[PMID: 29758517]
THP-1	CC₅₀	3.6 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29885575]
THP-1	IC₅₀	>10.8 μM Compound: Amphotericin B	Cytotoxicity against PMA-differentiated human THP1 cells after 72 hrs by MTT assay Cytotoxicity against PMA-differentiated human THP1 cells after 72 hrs by MTT assay	[PMID: 30034591]
THP-1	CC₅₀	>62.5 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
THP-1	IC₅₀	10 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells infected with Leishmania donovani MHOM/SD/62/1S-CL2D LdBOB amastigotes harboring eGFP assessed as reduction in cell number after 96 hrs by DAPI staining based microscopic analysis Cytotoxicity against human THP1 cells infected with Leishmania donovani MHOM/SD/62/1S-CL2D LdBOB amastigotes harboring eGFP assessed as reduction in cell number after 96 hrs by DAPI staining based microscopic analysis	[PMID: 30100019]
THP-1	EC₅₀	2 μM Compound: Amphotericin B	Cytotoxicity against human THP-1 cells Cytotoxicity against human THP-1 cells	[PMID: 30234295]
THP-1	CC₅₀	3.6 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 30655943]
THP-1	IC₅₀	>10 μM Compound: AmB	Cytotoxicity against human THP1 cells assessed as cell viability measured after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 31299585]
THP-1	CC₅₀	15.96 μM Compound: AmB	Cytotoxicity against macrophage-differentiated human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against macrophage-differentiated human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31419778]
THP-1	EC₅₀	27.85 μM Compound: AmB	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31702921]
THP-1	EC₅₀	>5 μM Compound: Amphotericin B	Cytotoxicity against human THP-1 cells by LDH assay Cytotoxicity against human THP-1 cells by LDH assay	[PMID: 33945281]
THP-1	CC₅₀	6 μM Compound: Amphotericin B	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition Cytotoxicity against human THP-1 cells assessed as cell growth inhibition	[PMID: 35810535]
THP-1	IC₅₀	14.86 μM Compound: AMB	Cytotoxicity against human THP-1 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay Cytotoxicity against human THP-1 cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay	[PMID: 36516584]
THP-1	CC₅₀	363.8 μM Compound: AmB	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by alamarblue staining based analysis Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by alamarblue staining based analysis	[PMID: 37156183]
THP-1	CC₅₀	23.1 μM Compound: AmB	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability by MTT assay	[PMID: 37729094]
THP-1	IC₅₀	14.86 μM Compound: AmB	Cytotoxicity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by resazurin staining based analysis Cytotoxicity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by resazurin staining based analysis	[PMID: 37859713]
THP-1	CC₅₀	21.1 μM Compound: AmpB	Cytotoxicity against PMA-differentiated human THP-1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against PMA-differentiated human THP-1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 38164929]
THP-1	CC₅₀	364 μM Compound: Amphotericin B	Cytotoxicity against human THP-1 cells incubated for 72 hrs by Alamar blue assay Cytotoxicity against human THP-1 cells incubated for 72 hrs by Alamar blue assay	[PMID: 38677111]
THP-1	CC₅₀	7.57 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells Cytotoxicity against human THP1 cells	10.1039/C3MD00299C
THP-1	EC₅₀	0.25 μM Compound: Amphotericin B	Antileishmanial activity against amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells assessed as parasite clearance after 3 days by Draq5 staining-based confocal microscopic analysis Antileishmanial activity against amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells assessed as parasite clearance after 3 days by Draq5 staining-based confocal microscopic analysis	10.1039/C3MD00299C
THP-1	EC₅₀	0.11 μM Compound: Amphotericin B	Antileishmanial activity against luciferase expressing Leishmania donovani intracellular amastigotes infected in human THP1 cells assessed as inhibition of parasite growth after 48 hrs by Bright-glo luciferase assay Antileishmanial activity against luciferase expressing Leishmania donovani intracellular amastigotes infected in human THP1 cells assessed as inhibition of parasite growth after 48 hrs by Bright-glo luciferase assay	10.1039/C5MD00119F
THP-1	EC₅₀	2.1 μM Compound: Amphotericin B	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 48 hrs by alamar blue dye based assay	10.1039/C5MD00119F
U-937	EC₅₀	0.05 μg/mL Compound: Amph	Antileishmanial activity against amastigote stage of Leishmania panamensis MHOM/CO/87/UA140-EpiR-GFP infected in human U937 cells assessed as parasite growth inhibition after 72 hrs by flow cytometric analysis Antileishmanial activity against amastigote stage of Leishmania panamensis MHOM/CO/87/UA140-EpiR-GFP infected in human U937 cells assessed as parasite growth inhibition after 72 hrs by flow cytometric analysis	[PMID: 25725376]
U-937	EC₅₀	0.04 μg/mL Compound: Amphotericin B	Leishmanicidal activity against intracellular amastigotes of Leishmania (Viannia) panamensis MHOM/CO/87/UA140pIR-GFP infected in human U937 cells assessed as decrease of intracellular parasite load after 72 hrs Leishmanicidal activity against intracellular amastigotes of Leishmania (Viannia) panamensis MHOM/CO/87/UA140pIR-GFP infected in human U937 cells assessed as decrease of intracellular parasite load after 72 hrs	[PMID: 26218652]
U-937	EC₅₀	0.04 μg/mL Compound: Amphotericin B	Leishmanicidal activity against intracellular amastigote stage of Leishmania panamensis MHOM/CO/87/UA140epir GFP infected in human U937 cells assessed as parasite viability after 72 hr by flow cytometric analysis Leishmanicidal activity against intracellular amastigote stage of Leishmania panamensis MHOM/CO/87/UA140epir GFP infected in human U937 cells assessed as parasite viability after 72 hr by flow cytometric analysis	10.1007/s00044-011-9886-8
Vero	IC₅₀	6.5 μg/mL Compound: Amphotericin B	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 15730255]
Vero	IC₅₀	6.5 μg/mL Compound: amphotericin B	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17134906]
Vero	IC₅₀	7 μg/mL Compound: AMB	Cytotoxicity against Vero cells by neutral red method Cytotoxicity against Vero cells by neutral red method	[PMID: 17181171]
Vero	CC₅₀	98.35 μM Compound: Amphotericin B	Cytotoxicity against Vero cells by MTT assay Cytotoxicity against Vero cells by MTT assay	[PMID: 17889546]
Vero	IC₅₀	0.25 μM Compound: Amphotericin B	Antiprotozoal activity against Leishmania chagasi PP75 in vero cells Antiprotozoal activity against Leishmania chagasi PP75 in vero cells	[PMID: 17889546]
Vero	IC₅₀	0.31 μM Compound: Amphotericin B	Antiprotozoal activity against Leishmania amazonensis 575 in vero cells Antiprotozoal activity against Leishmania amazonensis 575 in vero cells	[PMID: 17889546]
Vero	IC₅₀	7.5 μg/mL Compound: amphotericin B	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 19105653]
Vero	IC₅₀	6.5 μg/mL Compound: AmB	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 21134759]
Vero	IC₅₀	4.7 μg/mL Compound: AMB	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 21743827]
Vero	IC₅₀	0.33 μM Compound: Amphotericin B	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23727538]
Vero	IC₅₀	28.6 μg/mL Compound: AMB	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 23831506]
Vero	IC₅₀	1.1 μM Compound: ampB	Antitrypanosomal activity against Trypanosoma cruzi Sylvio X-10 amastigotes infected in African green monkey Vero cells assessed as eradication of amastigotes after 5 days by Giemsa staining-based assay Antitrypanosomal activity against Trypanosoma cruzi Sylvio X-10 amastigotes infected in African green monkey Vero cells assessed as eradication of amastigotes after 5 days by Giemsa staining-based assay	[PMID: 24749923]
Vero	IC₅₀	>100 μM Compound: Amphotericin B	Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]
Vero	CC₅₀	200 μM Compound: Amph B	Cytotoxicity against African green monkey Vero cells after 72 hrs by Alamar blue assay Cytotoxicity against African green monkey Vero cells after 72 hrs by Alamar blue assay	[PMID: 29758517]
Vero	CC₅₀	200 μM Compound: Amphotericin B	Cytotoxicity against African green monkey Vero cells after 72 hrs by plate reader based Alamar blue assay Cytotoxicity against African green monkey Vero cells after 72 hrs by plate reader based Alamar blue assay	[PMID: 30878827]
Vero	CC₅₀	8 μg/mL Compound: Amphotericin B	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 2 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 2 hrs by MTS assay	[PMID: 31962263]
Vero	CC₅₀	200 μM Compound: Amphotericin B	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by microplate alamar blue assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by microplate alamar blue assay	[PMID: 33091297]
Vero	IC₅₀	6.8 μM Compound: AMB	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by neutral red dye based assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by neutral red dye based assay	[PMID: 34283598]
Vero	IC₅₀	57.77 μM Compound: AMB	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay	[PMID: 36516584]
Vero	CC₅₀	~ 8 μg/mL Compound: Amphotericin B	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell viability incubated for 2 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell viability incubated for 2 hrs by MTS assay	[PMID: 37859711]
Vero	IC₅₀	57.8 μM Compound: AmB	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based analysis Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth incubated for 48 hrs by resazurin staining based analysis	[PMID: 37859713]
Vero	CC₅₀	3.7 μM Compound: PC2	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	10.1039/C5MD00599J
WI-38	CC₅₀	4.99 μM Compound: Amphotericin B	Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay	[PMID: 17893158]
WI-38	EC₅₀	1.67 μM Compound: Amphotericin B	Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay	[PMID: 17893158]

In Vitro

Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. Amphotericin B induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14^[1]. Amphotericin B interacts with cholesterol, the major sterol of mammal membranes, thus limiting the usefulness of Amphotericin B due to its relatively high toxicity. Amphotericin B is dispersed as a pre-micellar or as a highly aggregated state in the subphase^[2]. Amphotericin B only kills unicellular Leishmania promastigotes (LPs) when aqueous pores permeable to small cations and anions are formed. Amphotericin B (0.1 mM) induces a polarization potential, indicating K⁺ leakage in KCl-loaded liposomes suspended in an iso-osmotic sucrose solution. Amphotericin B (0.05 mM) exhibits a nearly total collapse of the negative membrane potential, indicating Na⁺ entry into the cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Amphotericin B results in prolonging the incubation time and decreasing PrPSc accumulation in the hamster scrapie model. Amphotericin B markedly reduces PrPSc levels in mice with transmissible subacute spongiform encephalopathies (TSSE)^[4]. Amphotericin B exerts a direct effect on Plasmodium falciparum and influences eryptosis of infected erythrocytes, parasitemia, and host survival in murine malaria. Amphotericin B tends to delay the increase of parasitemia and significantly delays host death plasmodium berghei-infected mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1397-89-3
Appearance Solid
Molecular Weight 924.08
Formel C₄₇H₇₃NO₁₇
Color Light yellow to yellow
SMILES

C[C@H]([C@@H](O)[C@@H](C)[C@H](C)OC1=O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@]2([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@]3([H])[C@H](C(O)=O)[C@@H](O)C[C@](C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C1)(O)O3
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Microorganisms
Streptomyces nodosus
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (27)

All OthersFlow CytometryIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cell

Melanopsin retinal ganglion cells mediate light-promoted brain development. [Abstract]

2022 Aug 18;185(17):3124-3137.e15. PMID: 35944541
J Nanobiotechnology

Cartilage progenitor cells derived extracellular vesicles-based cell-free strategy for osteoarthritis treatment by efficient inflammation inhibition and extracellular matrix homeostasis restoration. [Abstract]

2024 Jun 19;22(1):345. PMID: 38890638
Environ Sci Technol

Aquatic Toxicological Assessment of Solid Pyrolysis Product (SPP) from Synthetic Textile Feedstock Relative to Biochar, Carbon Black, and Activated Carbon. [Abstract]

2026 Apr 14;60(14):10525-10537. PMID: 41931823
Antioxidants (Basel)

Hyssopus cuspidatus Boriss Volatile Extract (SXC): A Dual-Action Antioxidant and Antifungal Agent Targeting Candida albicans Pathogenicity and Vulvovaginal Candidiasis via Host Oxidative Stress Modulation and Fungal Metabolic Reprogramming. [Abstract]

2025 Aug 25;14(9):1046. PMID: 41008953

Amphotericin B purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2025 Aug 25;14(9):1046. [Abstract]

Time–kill curves of C. albicans strains treated with AmB (MIC: 0.0625 μg/mL)-SXC and FLC-SXC combinations at fractional inhibitory concentration index (FICI) concentrations(Amphotericin B: AmB).
Virulence

The cyclin dependent kinase (CDK)7 inhibitor BS-181 inhibits pathogenic Cryptococcus species, causing G2/M arrest and a splicing defect. [Abstract]

2026 Dec;17(1):2629100. PMID: 41701636
Front Cell Infect Microbiol

Caenorhabditis elegans- Based Aspergillus fumigatus Infection Model for Evaluating Pathogenicity and Drug Efficacy. [Abstract]

2020 Jun 26;10:320. PMID: 32670897

Amphotericin B purchased from MedChemExpress. Usage Cited in: Front Cell Infect Microbiol. 2020 Jun 26;10:320. [Abstract]

Kaplan-Meier survival plots of C. elegans infected by KU80△ in the presence of antifungal drugs. The glp-4(bn2); sek-1(km4) worms were pre-infected with KU80△ for 8 h then transferred into liquid killing media containing different concentrations of Amphotericin B (1-2 μg/mL; 0-72 h).

Amphotericin B purchased from MedChemExpress. Usage Cited in: Front Cell Infect Microbiol. 2020 Jun 26;10:320. [Abstract]

Effect of antifungal treatment on Af293-dsRed infection to glp-4(bn2); sek-1(km4) worms. Images were taken under DIC and TRITC channels from DMSO treatment by 24 h, 1.5 μg/mL Amphotericin B (AmB) treatment by 48 h. Scale bar is 200 μm.
Am J Physiol Cell Physiol

Electrical stimulation facilitates the angiogenesis of human umbilical vein endothelial cells through MAPK/ERK signaling pathway by stimulating FGF2 secretion. [Abstract]

2019 Aug 1;317(2):C277-C286. PMID: 30995109
Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370
Neuropharmacology

Identification of a microglial activation-dependent antidepressant effect of amphotericin B liposome. [Abstract]

2019 Jun:151:33-44. PMID: 30954529
Probiotics Antimicrob Proteins

Screening the γ-core Motif Peptides of Ascomycetous Antifungal Proteins for Antifungal Activity and Potential Therapeutic Applicability. [Abstract]

2026 Jan 6. PMID: 41493708
Cancers (Basel)

Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy. [Abstract]

2022 Jul 21;14(14):3550. PMID: 35884614
Microbiol Spectr

Synergistic antifungal activity of minocycline as an effective augmenting agent of fluconazole against drug-resistant Candida tropicalis. [Abstract]

2025 Mar 31:e0318524. PMID: 40162832
Microbiol Spectr

In Vitro and In Vivo Evaluation of Synergistic Effects of Everolimus in Combination with Antifungal Agents on Exophiala dermatitidis. [Abstract]

2023 Jun 15;11(3):e0530222. PMID: 37140396

Amphotericin B purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2023 Jun 15;11(3):e0530222. [Abstract]

Changes in ROS generation ratio in Amphotericin B (1 μg/mL; 90 min) group. In flow cytometry analysis, the abscissa represents the relative fluorescence intensity, and the ordinate represents the spore count. The dark blue area represents the percentage of spores (P3) with emitted fluorescence after DHR-123 was oxidized. The peak value in the dark blue area indicates the largest number of oxidized spores under the corresponding fluorescence intensity.

Amphotericin B purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2023 Jun 15;11(3):e0530222. [Abstract]

Survival rates in mono-treatment and combination treatment groups. Note: The survival curves of larvae infected with E. dermatitidis after different interventions. Amphotericin B (AMB) (1 μg/mL) or AMB (0.25 μg/mL) combine with EVL can significantly improve the survival rate of larvae for 6 days.
J Virol

Interferon-Induced Transmembrane Protein 3 Is a Virus-Associated Protein Which Suppresses Porcine Reproductive and Respiratory Syndrome Virus Replication by Blocking Viral Membrane Fusion. [Abstract]

2020 Nov 23;94(24):e01350-20. PMID: 32999030
J Appl Microbiol

Enhanced in vitro antimicrobial activity of amphotericin B with berberine against dual-species biofilms of Candida albicans and Staphylococcus aureus. [Abstract]

2021 Apr;130(4):1154-1172. PMID: 32996236
Infect Drug Resist

Correlation Between Drug Resistance and Virulence of Candida Isolates from Patients with Candidiasis. [Abstract]

2022 Dec 15:15:7459-7473. PMID: 36544991
PeerJ

Antifungal effects of andrographolide and its combination with amphotericin B against selected fungal pathogens. [Abstract]

2025 Jun 16:13:e19544. PMID: 40538737
Toxicon

Hepatoprotective effect of diammonium glycyrrhizinate and neuroprotective effect of piperazine ferulate on AmB-induced liver and kidney injury by suppressing apoptosis in vitro and in vivo. [Abstract]

2024 Jun 5:246:107795. PMID: 38849008
J Mol Histol

β-Ionone inhibits A. sydowii mediated LUAD progression by inhibiting myeloid-derived suppressor cell (MDSC) expansion and activation. [Abstract]

2026 Jan 12;57(1):43. PMID: 41524781
J Mycol Med

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans. [Abstract]

2022 Mar;32(1):101227. PMID: 34800920
Phytochem Lett

2023 Aug, 56, 24-29.
University of Szeged

2026.
Patent

US20250235403A1.
Adv Biotechnol (Singap)

Simplifying the protocol for low-pollution-risk, efficient mouse myoblast isolation and differentiation. [Abstract]

2025 Mar 11;3(1):8. PMID: 40067554
Patent

US20240417738A1.
Evid Based Complement Alternat Med

Electroacupuncture at Bilateral Zusanli Points (ST36) Protects Intestinal Mucosal Immune Barrier in Sepsis. [Abstract]

2015:2015:639412. PMID: 26346309

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (54.11 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0822 mL

5.4108 mL

10.8216 mL

5 mM

0.2164 mL

1.0822 mL

2.1643 mL

10 mM

0.1082 mL

0.5411 mL

1.0822 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (2.25 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (2.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

THP-1 and HEK293 cells are transiently transfected using DEAE-dextran and Polyfect reagent, respectively. Plasmids transfected contain genes coding for the NF-κB-dependent pELAM-luc luciferase reporter, TLR2, TLR4, CD14, and MD2. Cells (5×10⁵ THP-1 or 1×10⁵ HEK293) are added to 12-well plates, washed after 18 h, and stimulated for 5 h. Cells are then lysed with reporter lysis buffer as directed, and lysates are analyzed for luminescence using Promega luciferase substrate and a Monolight 3010 luminometer.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

The kinetics of cell death induced by AmB against Leishmania promastigotes is followed by using fluorometry with the DNA-binding compound ethidium bromide (EB). Fluorescence measurements are performed on a SPEX Fluorolog II spectrophotometer at 365-580 nm excitation-emission wavelengths. Promastigotes at a final concentration of 25×10⁶ cells/mL are incubated for 5 min with gentle stirring in the fluorescence cuvette with 2 mL of different buffered solutions but always containing 10 mM glucose and EB (50 mM). After signal stabilization is achieved, AmB is added and dissolved in dimethylsulfoxide. Maximal EB incorporation is always obtained by adding digitonin (50 mg/mL). All solutions used are buffered with 75 mM TRIS (pH 4 7.6) and contain 150 mM NaCl (BNa⁺), 150 mM KCl (BK⁺), 150 mM choline chloride, and 100 mM sucrose, 100 mM NaCl. The osmolarity of all solutions is always adjusted to 390±5 mOsm using an advanced instrument SW2 osmometer.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sau K, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003 Sep 26;278(39):37561-8. Epub 2003 Jul 14. [Content Brief]

[2]. Barwicz J, et al. The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids. 1997 Feb 28;85(2):145-55. [Content Brief]

[3]. Ramos H, et al. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol. 1996 Jul;152(1):65-75. [Content Brief]

[4]. Demaimay R, et al. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol. 1994 Sep;75 (Pt 9):2499-503. [Content Brief]

[5]. Adams ML, et al. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules. 2003 May-Jun;4(3):750-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.0822 mL	5.4108 mL	10.8216 mL	27.0539 mL
	5 mM	0.2164 mL	1.0822 mL	2.1643 mL	5.4108 mL
	10 mM	0.1082 mL	0.5411 mL	1.0822 mL	2.7054 mL
	15 mM	0.0721 mL	0.3607 mL	0.7214 mL	1.8036 mL
	20 mM	0.0541 mL	0.2705 mL	0.5411 mL	1.3527 mL
	25 mM	0.0433 mL	0.2164 mL	0.4329 mL	1.0822 mL
	30 mM	0.0361 mL	0.1804 mL	0.3607 mL	0.9018 mL
	40 mM	0.0271 mL	0.1353 mL	0.2705 mL	0.6763 mL
	50 mM	0.0216 mL	0.1082 mL	0.2164 mL	0.5411 mL

Keywords

Amphotericin B

27 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Amphotericin B

Anti-Infection Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Lipid Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Antiparasitic Compound library

Microbial Metabolite Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Natural Product Diversity Scaffold Library

Classic FDA-Approved Drug Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Amphotericin B

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (27)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Amphotericin B Related Classifications

Art. -Nr.: HY-B0221